Drug Trial Radar · NCT01232504
Antifugal Effect of Recombinant Human Granulocyte-macrophage Stimulating Factor (rhGM-CSF) in Patients Post Allo-HSCT
Last checked: Nov 19, 2026Latest source record: Nov 4, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
206
Actual
Start
Sep 2009
Primary completion
Mar 2013
Study completion Jun 2013
Sponsor
- Lead sponsor
- Xiamen Amoytop Biotech Co., Ltd.Industry
- Sponsor type
- Industry
- Collaborators
- Shanghai Jiao Tong University Affiliated First People's Hospital
- First posted
- Nov 2, 2010
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Prevention
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
We conducted a prospective, multicenter, open-label randomized trial to compare the antifungal effect of Recombinant Human Granulocyte-macrophage Stimulating Factor (rhGM-CSF), Recombinant Human Granulocyte Stimulating Factor (rhG-CSF) or a combination of rhGM-CSF and rhG-CSF for neutropenic patients undergoing allogeneic stem cell transplantation.
Conditions
- Mycoses
Interventions
rhGM-CSF groupDrug
subcutaneous rhGM-CSF 5-7μg/kg/d , started on day 5 post-transplant and continued until recovery from neutropenia (absolute neutrophil count \[ANC\] \> 1.5×10(9)/L for 2 consecutive days).
rhG-CSF+rhGM-CSF groupDrug
a combination of 2-3μg/kg/d rhGM-CSF and 2-3μg/kg/d rhG-CSF each after transplantation, started on day 5 post-transplant and continued until recovery from neutropenia (absolute neutrophil count \[ANC\] \> 1.5×10(9)/L for 2 consecutive days).
rhG-CSF groupDrug
subcutaneous rhGM-CSF 5-7μg/kg/d , started on day 5 post-transplant and continued until recovery from neutropenia (absolute neutrophil count \[ANC\] \> 1.5×10(9)/L for 2 consecutive days).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidences of Invasive Fungal Diseases (IFD)Time frame: 100 day post transplant
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
The First Affiliated Hospital of Guangxi Medical University
Nanning, Guangxi, China
Henan Cancer Hospital
Zhengzhou, Henan, China
Wuhan Tongji Hospital
Wuhan, Hubei, China
Shanghai First People's Hospital
Shanghai, Shanghai Municipality, China
The First Affiliated Hospital of Xinjiang Medical University
Ürümqi, Xinjiang, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.